SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Sarepta Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| PMO Products [Member] | $965.57M | $967.17M | $944.52M | $843.77M | 43.9% | -0.2% |
| ELEVIDYS [Member] | $898.73M | $820.79M | $200.36M | $0 | 40.9% | +9.5% |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| United States | – | – | – | $747.10M | – | – |
| Non-US | – | – | – | $96.70M | – | – |
From the segment and revenue-disaggregation notes of Sarepta Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.